Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates

Onkologie

Volumn 36, Issue 1-2, 2013, Pages 53-59

  Berger, Karin ^a   Bauer, Matthaeus ^b   Schopohl, Dorothee ^a   Henschler, Reinhard ^a   Ostermann, Helmut ^c  

^a Department of Transfusion Medicine   (Germany)

^b Department of Medical Management ^*  (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute transfusion reaction; Cost; Haematology oncology patients; Pathogen inactivation; Pathogen reduction; Platelet transfusion

Indexed keywords

AMOTOSALEN; RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION REACTION; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMIC ASPECT; HEMATOLOGY EQUIPMENT; HUMAN; PATHOGEN REDUCTION TECHNOLOGY; SHELF LIFE; THROMBOCYTE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET C RADIATION; ULTRAVIOLET RADIATION;

BLOOD COMPONENT REMOVAL; COST SAVINGS; GERMANY; HEALTH CARE COSTS; MODELS, ECONOMIC; PLATELET TRANSFUSION;

EID: 84874310602     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000346309     Document Type: Article

References (45)

1. Apelseth TO, Hervig T, Bruserud O: Current practice and future directions for optimization of platelet transfusions in patients with severe therapyinduced cytopenia. Blood Rev 2011;25:113-122.
2. Stroncek DF, Rebulla P: Platelet transfusions. Lancet 2007;370:427-438.
3. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-613.
4. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R: Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114.
5. Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W: Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000;95:2514-2522.
6. Spiess BD: Platelet transfusions: the science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol 2010;24:65-83.
7. Seghatchian J, Hervig T, Putter JS: Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates. Transfus Apher Sci 2011; 45:75-84.
8. Kiefel V: Reactions induced by platelet transfusions. Transfus Med Hemother 2008;35:354-358.
9. Klein HG: How safe is blood, really? Biologicals 2010;38:100-104.
10. Rasonglès P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP: Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009;49:1083-1091.
11. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(suppl 2): 1S-29S.
12. Burger R, Offergeld R: Mitteilungen des Arbeitskreises Blut des Bundesministeriums für Gesundheit: Festlegung der Haltbarkeitsfrist von Thrombozytenkonzentraten mit dem Ziel der Reduktion lebensbedrohlicher septischer Transfusionsreaktionen durch bakterielle Kontamination. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2008;51:1484.
13. Walther-Wenke G: Incidence of bacterial transmission and transfusion reactions by blood components. Clin Chem Lab Med 2008;46:919-925.
14. Funk MB, Günay S, et al.: Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2009: Auswertung der Meldungen von schwerwiegenden Transfusionsreaktionen nach § 63c AMG. 2011; www.pei.de/SharedDocs/ Downloads/vigilanz/haemovigilanz/publikationen/haemovigillanz-bericht-2009.pdf? -blob=publicationFile&v=2; accessed 03/09/2012.
15. Funk MB, Günay S, et al.: Hämovigilanzbericht des Paul-Ehrlich-Instituts 2010: Auswertung der Meldungen von schwerwiegenden Transfusionsreaktionen nach § 63c AMG. 2012; www.pei.de/SharedDocs/ Downloads/vigilanz/haemovigilanz/publikationen/haemovigillanz-bericht-2010.pdf? -blob=publicationFile&v=2; accessed 03/09/2012.
16. Katalinic A, Peters E, Beske F, Pritzkuleit R: Projection of morbidity 2030 and 2050: impact for the national health system and blood supply. Transfus Med Hemother 2010;37:155-159.
17. Seifried E, Klueter H, Weidmann C, Staudenmaier T, Schrezenmeier H, Henschler R, Greinacher A, Mueller MM: How much blood is needed? Vox Sang 2011;100:10-21.
18. Henseler O: Paul-Ehrlich-Institut (PEI) report on blood supply 2011. www.pei.de/cln-227/nn-154580/sid-F49158C65AEA1AAE073BFAFC8CB7F0CE/EN/ information/blood-supply/reports/report-blood-supply-2010-2011-21tfg- contenthtml?-nnn-true; accessed 03/09/2012.
19. Ali A, Auvinen MK, Rautonen J: The aging population poses a global challenge for blood services. Transfusion 2010;50:584-588.
20. Greinacher A, Fendrich K, Brzenska R, Kiefel V, Hoffmann W: Implications of demographics on future blood supply: A population-based cross-sectional study. Transfusion 2011;51:1-8.
21. Gelderman MP, Chi X, Zhi L, Vostal JG: Ultraviolet b light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion. Transfusion 2011;51:2343-2357.
22. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA: Proceedings of a consensus conference: pathogen inactivationmaking decisions about new technologies. Transfus Med Rev 2008;22:1-34.
23. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard Ft, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the Sprint trial. Blood 2004;104:1534-1541.
24. Irsch J, Lin L: Pathogen inactivation of platelet and plasma blood components for transfusion using the intercept blood system. Transfus Med Hemother 2011;38:19-31.
25. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: Impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011;51:622-629.
26. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Herve P: Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002;42:1356-1364.
27. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L: A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008;48:1061-1071.
28. Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, Schneider H, Burchardi H: Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 2002;28:1440-1446.
29. Moeremans K, Warie H, Annemans L: Assessment of the economic value of the intercept blood system in Belgium. Transfus Med 2006;16:17-30.
30. Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U: Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003;25:2464-2486.
31. Staginnus U, Corash L: Economics of pathogen inactivation technology for platelet concentrates in japan. Int J Hematol 2004;80:317-324.
32. De Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk Kooy M, Bins M, van Prooijen HC: Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000;40:398-403.
33. Berger K, Klein HG, Seitz R, Schramm W, Spieser JM: The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components. Biologicals 2011;39:189-193.
34. Schmidt M, Sireis W, Seifried E: Implementation of bacterial detection methods into blood donor screening-overview of different technologies. Transfus Med Hemother 2011;38:259-265.
35. Pearce S, Rowe GP, Field SP: Screening of platelets for bacterial contamination at the welsh blood service. Transfus Med 2011;21:25-32.
36. Walther-Wenke G, Wirsing von Konig CH, Daubener W, Heiden M, Hoch J, Hornei B, Volkers P: Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang 2011;100: 359-366.
37. Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, Rasongles P, Garraud O, Richard P, Schooneman F, Vezon G, Al Radwan R, Brand A, Hervig T, Castro E, Lozano M, Navarro L, Puig L, Almazan C, MacLennan S, Cardigan R, Franklin IM, Prowse C: Pathogen inactivation of platelet concentrates. Vox Sang 2010;99:85-95.
38. Schlenke P, Hagenah W, Irsch J, Sundin D, Corash L, Lin L, Kirchner H, Wagner T: Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients. Ann Hematol 2011;90: 1457-1465.
39. Veihola M, Aroviita P, Linna M, Sintonen H, Kekomaki R: Variation of platelet production and discard rates in 17 blood centers representing 10 European countries from 2000 to 2002. Transfusion 2006;46:991-995.
40. Böger RH, Schmidt G: Chapter 16. Antirheumatika und Antiphlogistika; in Schwabe U, Paffrath D (eds): Arzneiverordnungs-Report 2012-aktuelle Daten, Kosten, Trends und Kommentare. Berlin, Heidelberg: Springer 2012; ISBN 978-3-642-29241-5.
41. Agence nationale de sécurité du médicament et des produits de santé (ansm) rapport d'activité hémovigilance 2011. (juillet 2012).ansmsantefr/Mediatheque/Publications/Bilans-Rapports- dactivite-Bilans-et-rapports-d-activite#folder-26762.
42. Bolton-Maggs PBH (ed) and Cohen H on behalf of the Serious Hazards of Transfusion (SHOT) steering group: The 2011 Annual SHOT Report (2012). ISBN 978-0-9558648-4-1. www.shotuk.org/shotreports/shot-annual-report-summary-2011/.
43. Leben in der EU; data from 2010. europaeu/documentation/statistics-polls/ index-dehtm; accessed 09/07/2012.
44. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L: An active haemovigilance programme characterizing the safety profile of 7,437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008;94:315-323.
45. Funk MB, Günay S, Lohmann A, Henseler O, Keller-Stanislawski B: [Evaluation of measures aimed to reduce serious adverse transfusion reactions (hemovigilance data from 1997 to 2008)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010;53:347-356.